UPMC Hillman Cancer Center

University of Pittsburgh Medical Center (UPMC)

Pittsburgh, PA

Sorting 5 by

Accepting patients

Graft Versus Host Disease-Reduction Strategies

A Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients With Acute Leukemia or Myelodysplastic Syndrome: Selective Depletion of CD45RA+ Naïve T Cells (TND) vs. Post-Transplantation Cyclophosphamide (PTCy)
Learn more
  • Allogeneic Stem Cell Transplant
  • Phase 2

Not yet accepting

KER-050

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Learn more
  • Growth Factor
  • Phase 2
  • Has results

Not yet accepting

BGB-11417

A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies
Learn more
  • BCL-2 Inhibitor
  • Phase 1/2
  • Has results

Accepting patients

Interferon-γ With Donor Leukocyte Infusion

A Phase 2 Trial of Interferon-γ (IFN-γ) in Combination With Donor Leukocyte Infusion (DLI) to Treat Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) After Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
Learn more
  • Donor Lymphocyte Infusion (DLI)
  • Phase 2

Accepting patients

Collection of Tissue Samples for Cancer Research

Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)
Learn more
  • Observational Trial